In vivo adenovirus-mediated gene transfer for Parkinson's disease.
Identifieur interne : 001398 ( PubMed/Checkpoint ); précédent : 001397; suivant : 001399In vivo adenovirus-mediated gene transfer for Parkinson's disease.
Auteurs : P. Horellou [France] ; A. Bilang-Bleuel ; J. MalletSource :
- Neurobiology of disease [ 0969-9961 ] ; 1997.
English descriptors
- KwdEn :
- MESH :
- genetics : Adenoviridae, Genetic Vectors.
- therapy : Parkinson Disease.
- Animals, Genetic Therapy, Humans.
Abstract
Gene therapy is a potentially powerful approach to the treatment of neurological diseases. Neurotransmitter synthesizing enzymes and neurotrophic factors inhibiting neurodegenerative processes provide the basis for current development of gene therapy strategies for Parkinson's disease. Recently, in vivo gene transfer to the brain has been developed using adenovirus vectors. One of the advantages of recombinant adenovirus is that it can transduce both quiescent and actively dividing cells, thereby allowing both direct in vivo gene transfer and ex vivo gene transfer to neural cells. The expression of adenoviral vectors persists for several months with little inflammation, probably because the brain is partially protected from the immune system. Recombinant adenoviruses are currently being improved, particularly by inactivating viral genes controlling the expression of immunodominant viral proteins. Novel therapeutic tools such as vectors for gene therapy have to be evaluated in terms of efficacy and safety for future clinical trials. These vectors still need to be improved to allow long-term and possibly regulatable expression of the transgene.
DOI: 10.1006/nbdi.1997.0162
PubMed: 9361305
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:9361305Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vivo adenovirus-mediated gene transfer for Parkinson's disease.</title><author><name sortKey="Horellou, P" sort="Horellou, P" uniqKey="Horellou P" first="P" last="Horellou">P. Horellou</name><affiliation wicri:level="3"><nlm:affiliation>C 9923 CNRS, Laboratoire de Génétique Moléculaire de la Neurotransmission et des Processus Dégénératifs, Hôpital de la Pitié Salpêtrière, Bâtiment CERVI, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>C 9923 CNRS, Laboratoire de Génétique Moléculaire de la Neurotransmission et des Processus Dégénératifs, Hôpital de la Pitié Salpêtrière, Bâtiment CERVI, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bilang Bleuel, A" sort="Bilang Bleuel, A" uniqKey="Bilang Bleuel A" first="A" last="Bilang-Bleuel">A. Bilang-Bleuel</name></author><author><name sortKey="Mallet, J" sort="Mallet, J" uniqKey="Mallet J" first="J" last="Mallet">J. Mallet</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9361305</idno><idno type="pmid">9361305</idno><idno type="doi">10.1006/nbdi.1997.0162</idno><idno type="wicri:Area/PubMed/Corpus">001553</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001553</idno><idno type="wicri:Area/PubMed/Curation">001512</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001512</idno><idno type="wicri:Area/PubMed/Checkpoint">001512</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001512</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">In vivo adenovirus-mediated gene transfer for Parkinson's disease.</title><author><name sortKey="Horellou, P" sort="Horellou, P" uniqKey="Horellou P" first="P" last="Horellou">P. Horellou</name><affiliation wicri:level="3"><nlm:affiliation>C 9923 CNRS, Laboratoire de Génétique Moléculaire de la Neurotransmission et des Processus Dégénératifs, Hôpital de la Pitié Salpêtrière, Bâtiment CERVI, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>C 9923 CNRS, Laboratoire de Génétique Moléculaire de la Neurotransmission et des Processus Dégénératifs, Hôpital de la Pitié Salpêtrière, Bâtiment CERVI, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bilang Bleuel, A" sort="Bilang Bleuel, A" uniqKey="Bilang Bleuel A" first="A" last="Bilang-Bleuel">A. Bilang-Bleuel</name></author><author><name sortKey="Mallet, J" sort="Mallet, J" uniqKey="Mallet J" first="J" last="Mallet">J. Mallet</name></author></analytic><series><title level="j">Neurobiology of disease</title><idno type="ISSN">0969-9961</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviridae (genetics)</term><term>Animals</term><term>Genetic Therapy</term><term>Genetic Vectors (genetics)</term><term>Humans</term><term>Parkinson Disease (therapy)</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenoviridae</term><term>Genetic Vectors</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Genetic Therapy</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Gene therapy is a potentially powerful approach to the treatment of neurological diseases. Neurotransmitter synthesizing enzymes and neurotrophic factors inhibiting neurodegenerative processes provide the basis for current development of gene therapy strategies for Parkinson's disease. Recently, in vivo gene transfer to the brain has been developed using adenovirus vectors. One of the advantages of recombinant adenovirus is that it can transduce both quiescent and actively dividing cells, thereby allowing both direct in vivo gene transfer and ex vivo gene transfer to neural cells. The expression of adenoviral vectors persists for several months with little inflammation, probably because the brain is partially protected from the immune system. Recombinant adenoviruses are currently being improved, particularly by inactivating viral genes controlling the expression of immunodominant viral proteins. Novel therapeutic tools such as vectors for gene therapy have to be evaluated in terms of efficacy and safety for future clinical trials. These vectors still need to be improved to allow long-term and possibly regulatable expression of the transgene.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9361305</PMID><DateCreated><Year>1997</Year><Month>12</Month><Day>10</Day></DateCreated><DateCompleted><Year>1997</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0969-9961</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>3-4</Issue><PubDate><Year>1997</Year></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol. Dis.</ISOAbbreviation></Journal><ArticleTitle>In vivo adenovirus-mediated gene transfer for Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>280-7</MedlinePgn></Pagination><Abstract><AbstractText>Gene therapy is a potentially powerful approach to the treatment of neurological diseases. Neurotransmitter synthesizing enzymes and neurotrophic factors inhibiting neurodegenerative processes provide the basis for current development of gene therapy strategies for Parkinson's disease. Recently, in vivo gene transfer to the brain has been developed using adenovirus vectors. One of the advantages of recombinant adenovirus is that it can transduce both quiescent and actively dividing cells, thereby allowing both direct in vivo gene transfer and ex vivo gene transfer to neural cells. The expression of adenoviral vectors persists for several months with little inflammation, probably because the brain is partially protected from the immune system. Recombinant adenoviruses are currently being improved, particularly by inactivating viral genes controlling the expression of immunodominant viral proteins. Novel therapeutic tools such as vectors for gene therapy have to be evaluated in terms of efficacy and safety for future clinical trials. These vectors still need to be improved to allow long-term and possibly regulatable expression of the transgene.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horellou</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>C 9923 CNRS, Laboratoire de Génétique Moléculaire de la Neurotransmission et des Processus Dégénératifs, Hôpital de la Pitié Salpêtrière, Bâtiment CERVI, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilang-Bleuel</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mallet</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>59</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>11</Month><Day>15</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9361305</ArticleId><ArticleId IdType="pii">S0969-9961(97)90162-5</ArticleId><ArticleId IdType="doi">10.1006/nbdi.1997.0162</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Bilang Bleuel, A" sort="Bilang Bleuel, A" uniqKey="Bilang Bleuel A" first="A" last="Bilang-Bleuel">A. Bilang-Bleuel</name><name sortKey="Mallet, J" sort="Mallet, J" uniqKey="Mallet J" first="J" last="Mallet">J. Mallet</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Horellou, P" sort="Horellou, P" uniqKey="Horellou P" first="P" last="Horellou">P. Horellou</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001398 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001398 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:9361305
|texte= In vivo adenovirus-mediated gene transfer for Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:9361305" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |